Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> ABBVIE Latest News

19 HOURS AGO - TheStreet

A Must Read - Share

Amicus Acquires Scioderm, Adds Drug for Rare Skin Disorder to Pipeline

CRANBERRY, NJ (TheStreet) -- Amicus Therapeutics is expanding its pipeline of rare-disease drugs by acquiring privately held Scioderm, the developer of a topical cream to treat patients with a genetic disorder that causes extremely fragile skin susceptible to blisters and tears from even the lightest touch. Scioderm is being purchased for $229 million in cash and Amicus stock, according to ...

Tags: Amicus Acquires Scioderm, Adds Drug for Rare Skin Disorder to Pipeline,  Abbvie Latest News

AUG 31, 2015 - TheStreet

A Must Read - Share

CELG, PFE, REGN, RCPT Jim Cramer's Views

NEW YORK (Real Money) -- Jim Cramer shares his views every day on RealMoney. Click here for a real-time look at his insights and musings. How China's Troubles Affect Biotech and Pharma Stocks, Part 1 Posted at 6:12 a.m. EDT on Thursday, Aug. 27, 2015 The question's a simple one on its face: "what do the biotechs and new old/pharma have to do ...

Tags: CELG, PFE, REGN, RCPT Jim Cramer's Views,  Abbvie Latest News

AUG 21, 2015 - TheStreet

A Must Read - Share

AbbVie or Baxalta: Which Is the Better Biopharma Investment Today?

NEW YORK (TheStreet) -- AbbVie is one of the largest biopharmaceutical companies in the world with its market cap of $111.7 billion. But it has much in common with a company just one-quarter its size: Baxalta . Both were created by spinoffs: Abbott Laboratories spun off AbbVie in 2013. Baxter International spun off Baxalta this year. Must Read: Warren Buffett's Top 10 ...

Tags: AbbVie or Baxalta: Which Is the Better Biopharma Investment Today?,  Abbvie Latest News

AUG 20, 2015 - Zacks Investment Research

A Must Read - Share

United Therapeutics to Sell Priority Review Voucher to AbbVie

United Therapeutics' (UTHR) priority review voucher fetched $350 million in a deal with AbbVie; Unituxin approved in the EU for high-risk neuroblastoma in children.

Tags: United Therapeutics to Sell Priority Review Voucher to AbbVie,  Abbvie Latest News

AUG 19, 2015 - Benzinga

A Must Read - Share

Benzinga's M&A Chatter for Wednesday August 19, 2015

The following are the M&A deals, rumors and chatter circulating on Wall Street for Wednesday August 19, 2015: United Therapeutics to Sell Priority Review Voucher to AbbVie for $350M The Deal:

Tags: Benzinga's M&A Chatter for Wednesday August 19, 2015,  Abbvie Latest News